- Home
- OPTH vs ESLA Comparison
OPTH vs ESLA Comparison
Compare OPTH & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTH | ESLA |
|---|---|---|
| Founded | N/A | 2021 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 30.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPTH | ESLA |
|---|---|---|
| Price | $4.78 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 23.4K | ★ 24.2K |
| Earning Date | N/A | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.00 | $0.68 |
| 52 Week High | $5.45 | $3.15 |
Technical Indicators
Market Signals| Indicator | OPTH | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.38 | 47.51 |
| Support Level | $4.48 | $0.70 |
| Resistance Level | $5.08 | $1.35 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 34.78 | 52.30 |
Price Performance
Historical ComparisonAbout OPTH Optimi Health Corp. Common Shares
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.